Author: ainewsupdate

President Trump signed an executive order promoting artificial intelligence (AI) in K-12 education, aiming to prepare the U.S. workforce for technological advancements. The White House cited the need to maintain global leadership in the “technological revolution.”

Adeel Khan, CEO of Magic School AI, a leading generative AI platform for education, supports the initiative, arguing that a nation prioritizing AI must prepare its youth. While acknowledging AI’s potential benefits, Khan cautioned against its misuse, emphasizing the importance of critical thinking and student agency. His company offers AI tools to enhance writing, providing feedback to improve student work instead of replacing the student’s thought process.

In contrast, Sherry East, president of the South Carolina Education Association, expressed frustration with the executive order. East argued that teachers are already familiar with AI tools and that the order is unnecessary. She pointed out that the order’s call for training aligns with existing Department of Education programs, like Title II funds for professional development. East questioned the need for a new executive order when existing mechanisms are already in place.

The American Psychological Association noted that AI has been integrated into classrooms for years, supporting learning platforms like Google Classroom and Turnitin. This suggests that AI is already part of the educational landscape and that the executive order might be redundant.

Silicon Valley touts generative AI as a cure-all for disease, promising breakthroughs within a decade. Executives like Demis Hassabis and Sam Altman are making bold claims, but the reality is more nuanced. While generative AI holds significant promise for accelerating scientific discovery, it’s unlikely to replace human researchers.

The technology currently excels at synthesizing existing scientific literature, providing summaries and insights. Tools like OpenAI’s and Google’s AI models can sift through mountains of research, highlighting potential connections and hypotheses. However, these tools are prone to “hallucinating” – producing false or inaccurate information – and cannot generate truly novel scientific reasoning.

A more promising approach involves collaborative AI systems. Google’s “AI co-scientist,” for instance, generates and evaluates hypotheses in biomedical research. Researchers like Tiago Costa and José Penadés have seen this tool propose novel insights, leading to breakthroughs that human teams might not have found as quickly. Crucially, this AI acts as a powerful tool for increasing efficiency, not replacing human judgment.

AI also has a powerful role in accelerating and refining existing biological modeling, such as in protein folding. Tools like AlphaFold and similar AI programs can sift through vast amounts of experimental data to accelerate drug discovery and repurposing, and to help scientists better balance various design constraints. Companies like Pfizer and Moderna are using AI to identify potential drug targets.

Despite the potential, there are significant limitations. AI systems require high-quality training data and human oversight to ensure accuracy and prevent errors. Drug development still necessitates extensive laboratory and clinical trials, which AI currently cannot simulate. Generating novel ideas is not the primary challenge; evaluating those ideas remains expensive and complex, requiring both scientific expertise and rigorous testing.

The future of AI in science is likely one of collaboration, not replacement. AI can significantly improve the efficiency of scientific workflows, but human ingenuity, expertise, and experimental validation remain essential. The most effective application of AI in science will involve humans and AI working together to ask the right questions, curate relevant data, and scrutinize the outputs of these systems.